Enter your mobile number below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
Getting the download link through email is temporarily not available. Please check back later.

  • Apple
  • Android
  • Windows Phone
  • Android

To get the free app, enter your mobile phone number.

The New Players in Life Sciences Innovation: Best Practices in R&D from Around the World, The (FT Press Operations Management) 1st Edition

4.1 out of 5 stars 8 customer reviews
ISBN-13: 978-0132119900
ISBN-10: 0132119900
Why is ISBN important?
ISBN
This bar-code number lets you verify that you're getting exactly the right version or edition of a book. The 13-digit and 10-digit formats both work.
Scan an ISBN with your phone
Use the Amazon App to scan ISBNs and compare prices.
Have one to sell? Sell on Amazon
Buy used
$12.41
Condition: Used - Good
In Stock. Sold by Clearwater Village Books
Condition: Used: Good
Comment: Connecting readers with great books since 1972. Used books may not include companion materials, some shelf wear, may contain highlighting/notes, and may not include cd-rom or access codes. Customer service is our top priority!
Access codes and supplements are not guaranteed with used items.
16 Used from $12.41
+ $3.99 shipping
More Buying Choices
10 New from $51.99 16 Used from $12.41
Free Two-Day Shipping for College Students with Prime Student Free%20Two-Day%20Shipping%20for%20College%20Students%20with%20Amazon%20Student


Security
ITPro.TV Video Training
Take advantage of IT courses online anywhere, anytime with ITPro.TV. Learn more.
click to open popover

Editorial Reviews

From the Back Cover

“A wealth of insights and foresights about the global rise of the knowledge-based industry. Drivers and modulators from emerging economies make it necessary to look beyond the usual industry sector horizon. Using The New Players in Life Science Innovation’s well researched and comprehensive road map of India and China’s approach for becoming future innovative R&D players offers a strong medicine to business leaders who want to build organizations with an understanding on how the future may unfold.”

Martina Flammer, Senior Director, Emerging Markets, Pfizer Inc.

 

“This is a stimulating and original take on the changes in the life sciences industry worldwide.”

Helen Lawton Smith, Chair, Management Department, Birkbeck College, University of London

 

“Really understanding the evolution in science and technology around the world demands numbers and analysis, which can be very difficult to find and combine in a clear manner, but that’s just what readers get in The New Players in Life Science Innovation.”

Mike May, Editorial Director, Scientific American Worldview

 

The New Players in Life Science Innovation is a valuable resource for academics, policy makers, and practitioners alike as it deals in breadth and depth with currently key related issues in the areas of R&D management, policies, and practices and in the context of a world that is increasingly globalizing as well as dividing. Insights from this book will remain relevant for some time and may well provide prophetic as well. I highly recommend it as a key resource for both academic as well as policy and practice contexts.”

Elias Caryannis, Professor of Science, Technology, Innovation, and Entrepreneurship, School of Business, George Washington University

 

“The book documents that science-based business is no longer the exclusive domain of the West. In the future, competitors from emerging economies will be playing increasingly important roles in life science innovation. This trend is gathering momentum and is indeed irreversible.”

Y. Eugene Pak, Director of R&D Sector, Seoul National University Advanced Institutes of Convergence Technology

 

“Emerging partners and emerging markets are now key. Mroczkowski documents finally what we’ve been seeing individually as practitioners in technology transfer and biotech business development in recent years. These new regional partners and markets are no longer limited to late stage adaptors or me-too manufacturers, but have the technological capacity and financial strength to push novel early-stage biotech discoveries to market.”

Steven M. Ferguson, CLP, Chair, Technology Transfer, Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH

 

The global center of gravity in life sciences innovation is rapidly shifting East, just as it did in manufacturing. In this book, Tomasz Mroczkowski explains how China and other new economic powers are rapidly gaining leadership roles in the biosciences industries and thoroughly assesses the implications.

 

Mroczkowski discusses the sophisticated innovation strategies and reforms these nations have implemented: approaches that don’t rely on market forces alone and that are achieving remarkable success. Next, he previews the emerging global “bioeconomy,” in which life science discoveries will be applied pervasively in markets ranging from health to fuels.

 

As R&D in the West becomes increasingly costly, Mroczkowski introduces new options for partnering with new players. He thoroughly covers clinical trials, bioparks, technology zones, and emerging clusters, as well as global R&D collaboration strategies such as those of Eli Lilly, Merck, Novartis, and IBM.

 

With innovation-driven industries increasingly dominating the global economy, this book’s lessons and insights are indispensable for every R&D decision-maker and investor.

 

Tracking the massive power shift in global R&D and innovation

How emerging players and economies are transforming the life sciences industries

 

Closing the creativity gap: how Asia is moving toward qualitative parity

From capitalist revolution to innovation revolution: embracing “knowledge economics”

 

Globalizing clinical trials: beyond cost reduction

Understanding the unique opportunities and challenges of global clinical trials

 

Paradigm shifts, research plateaus, and the globalization of discovery

Collaborating worldwide in the new global bioeconomy

About the Author

Tomasz Mroczkowski is a full professor of International Business at the Kogod School of Business, American University in Washington, DC. He currently teaches international business and management in emerging economies in the Kogod School’s MBA program, and teaches in the special Master’s program in biotechnology management at the ESCP-Europe business school in Paris, France. His areas of research include innovation and business development in emerging economies, international outsourcing, and globalization of R&D in the life science and biotech industries. He is author of some 90 works published in the United States, UK, Japan, India, and Poland.

 

Mroczkowski has guest lectured at the National Defense Academy of Japan, Copenhagen Business School, University of Cambridge, and University of Paris-Sorbonne. He has also conducted executive seminars for leading companies including GM, AT&T, Union Carbide, GE, and Polaroid. He is Academic Director of the Institute for Private Enterprise and Democracy in Warsaw, advised Poland’s Minister of Foreign Trade, and currently advises Wroclaw’s EIT+ high technology zone.

 

He has been featured on the NBC Nightly News, was interviewed by Tokyo Shinbun and Shinichi Shinbun, and contributed to the AsianWall Street Journal and the JapanTimes. He holds a B.A. and an M.S. from Jagiellonian University, and a Ph.D. from the University of Economics, Krakow, Poland.

NO_CONTENT_IN_FEATURE

New York Times best sellers
Browse the New York Times best sellers in popular categories like Fiction, Nonfiction, Picture Books and more. See more

Product Details

  • Series: FT Press Operations Management
  • Hardcover: 352 pages
  • Publisher: FT Press; 1 edition (July 25, 2011)
  • Language: English
  • ISBN-10: 0132119900
  • ISBN-13: 978-0132119900
  • Product Dimensions: 6.3 x 0.9 x 9.2 inches
  • Shipping Weight: 1.3 pounds
  • Average Customer Review: 4.1 out of 5 stars  See all reviews (8 customer reviews)
  • Amazon Best Sellers Rank: #2,625,003 in Books (See Top 100 in Books)

Customer Reviews

Top Customer Reviews

By Jijnasu Forever VINE VOICE on September 26, 2011
Format: Hardcover Vine Customer Review of Free Product ( What's this? )
The premise of the book is very interesting - how will R&D in a critical domain evolve based on the key emerging trends and what are the best practices in the new landscape. Unfortunately, the book fails to live up to the promise.

The first three chapters provide a very laborious, repetitive analysis of the emerging countries in life sciences. Based on various government reports and other observations, the author convinces the reader that the "usual suspects" of emerging markets (Brazil, India, China...) are involved in Life Sciences as well. Other than highlighting the role of Singapore as a key player - these three chapters does nothing to advance a reader's understanding of the changing landscape.

While the author outlines three key emerging trends - clinical trials, drug discovery and formation of technology clusters, they lack a discussion on how the author identified these three areas to focus on. The dependence on a PriceWaterCooper analysis on the future of discovery process provides a very unoriginal and incomplete framing for the discussion that follows.

The chapter on Contract Research organizations (CROs) clearly makes the (obvious) point that outsourcing is increasing in clinical trials. Depending mostly on a single source - an analysis by Kearney et al., the chapter doesn't provide any new information other than a superficial summary and a very short section on the "future" using a very typical consultant chart from PwC - no original analysis. The same approach (and hence the problems) are reflected in the next chapter on technology clusters. The concluding chapters discuss approaches of Lilly, Merck and Pfizer - mostly relying on their respective press releases - without providing a critical analysis.
Read more ›
Comment 2 people found this helpful. Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
Format: Hardcover Vine Customer Review of Free Product ( What's this? )
This is first rate, within the limits of its aims. Those limits are that it is research-centered, focused on a specific industry and set of ecosystems, and descriptive rather than normative. It deserves a broader audience, which it is unlikely to get, primarily because of the absurdity of academic book publishing, where the very opposite of incentive pricing applies; the smaller the market, the higher the price, which reduces sales to the Average Reader and stiffs students in the case of textbooks and gouges college libraries for monographs and specialist works. At $49 hardback and $39 on Kindle, this won't be a best seller.

It merits a broad readership because it captures not just the dynamics of life sciences but of general shifts in global business in many other sectors. The analysis is well-grounded, full of data and examples that are instructive and embedded in a clear structure and set of organizing themes. It is very rich in illustrations from sectors, companies and countries. Overall, it is just what you wanted in your professors in the classroom: shrewd realism and practical knowledge of the field reinforced by scholarly depth, information that makes it all come alive, and lucid explanation and exegesis.

I found it a very welcome resource for my own work. I need to add a truth in reviewing caveat here. I am a Research Fellow in my semi-retired dotage at the very same institution as the author, American University's Kogod School of Business. He and I have not met and I am unfamiliar with his other work.
Read more ›
Comment One person found this helpful. Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
Format: Hardcover Vine Customer Review of Free Product ( What's this? )
After manufacturing, software and IT enabled services, now it is the time for the Life Science Industry to experience the effects of Globalization. Tomasz Mrockzkowski shows how R&D in life sciences is shifting from the Western countries to new global powerhouses like China and India. He compares the emerging innovation systems and national policies of China, India, Singapore, South Korea, and Brazil and evaluates their strengths and weaknesses in Pharmaceuticals, R&D, clinical trials and infrastructure creation. The critical study of the developments in differenct countries across the world gives not only very useful statistics, but also provides the framework for companies as well as entrepreneurs to take advantage of the global shifts in growth.

Strategies of the largest multinational pharmaceutical companies in their R&D collaborations with the developing world are explored in depth, which reveals how jobs as well as knowledge are now moving out from US and Europe to China and India. Leading companies of China and India are also covered along with a summary of their growth path. Inspite of being much smaller than the large multinationals, these companies are able to compete not only in their home turf but also in other countries through M&As and collaborations. But the developing countries are still well behind in basic research - how fast will they catch up? Which type of national policies will work? Will the investments in bioparks, technology zones and special economic zones create clusters that can accelerate innovation? Will their educational institutions be able to develop sufficient trained manpower? These are some of the interesting questions that the author tries to answer.
Read more ›
Comment One person found this helpful. Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse